# A Study of CNA3103 (LGR5-targeted, Autologous CAR-T Cells) Administered to Subjects With Metastatic Colorectal Cancer

Source: https://onco.cc/trials/nct05759728/  
OnCo record `nct05759728` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of CNA3103: 5 x 10^7 cells in colorectal cancer, run by Carina Biotech Limited, now recruiting.

## Summary

A Study of CNA3103 (LGR5-targeted, Autologous CAR-T Cells) Administered to Subjects With Metastatic Colorectal Cancer is a phase 1/2 interventional study registered as NCT05759728 by Carina Biotech Limited, with 45 participants planned, started 2023-10-24 and due to reach its primary completion in 2027-12. Interventions recorded: CNA3103: 5 x 10^7 cells, CNA3103: 1.5 x 10^8 cells, CNA3103: 4.5 x 10^8 cells, CNA3103: 1.5 x 10^9 cells, CNA3103: 2.5 x 10^7 cells and CNA3103: 6.75 × 10^8 cells.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT05759728
- Phase: 1/2
- Setting: A Phase 1/2a, Multicenter, Open-Label, Dose Escalation and Expansion Study of CNA3103 (LGR5-targeted, Autologous CAR-T Cells) Administered to Adult Subjects With Metastatic Colorectal Cancer
- Sponsor: Carina Biotech Limited
- Enrolled: 45

## Sources

- ClinicalTrials.gov NCT05759728: https://clinicaltrials.gov/study/NCT05759728

## Connected records

- cancers: [Colorectal cancer](https://onco.cc/cancers/colorectal/)

---
JSON: https://onco.cc/api/v1/entities/nct05759728.json